Hypodiploidy is a major prognostic factor in multiple myeloma

Blood

Volumn 98, Issue 7, 2001, Pages 2229-2238

  Smadja, Nicole Véronique ^a,b,c,d,e   Bastard, Christian ^a,b,c,d   Brigaudeau, Christophe ^a,b,c,d   Leroux, Dominique ^a,b,c,d   Fruchart, Christophe ^a,b,c,d  

^a HÔPITAL SAINT ANTOINE   (France)

^b INSERM   (France)

^c DUPUYTREN UNIVERSITY HOSPITAL   (France)

^d LE HAVRE HOSPITAL   (France)

^e Service Pr JL Taillemite   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA 2 MICROGLOBULIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN; MELPHALAN; PREDNISONE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 1; CHROMOSOME 11; CHROMOSOME 13; CHROMOSOME 8; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; DIPLOIDY; FEMALE; HUMAN; HYPODIPLOID; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS;

EID: 0035496928     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.7.2229     Document Type: Article

References (53)

1. Boccadoro M, Pileri A. Diagnosis, prognosis, and standard treatment of multiple myeloma. Hematol Oncol Clin North Am. 1997;11:111-131.
2. Kyle RA. Why better prognostic factors for multiple myeloma are needed. Blood. 1994;83:1713-1716.
3. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood. 1998;91:3-21.
4. Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med. 1997;336:1657-1664.
5. Davies FE, Jack AS, Morgan GJ. The use of biological variables to predict outcome in multiple myeloma. Br J Haematol. 1997;99:719-725.
6. 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood. 1993;81: 3382-3387.
7. Pérez-Simon JA, Garcia-Sanz R, Tabernero MD, et al. Prognostic value of numerical chromosome aberrations in multiple myeloma: a FISH analysis of 15 different chromosomes. Blood. 1998;91: 3366-3371.
8. Zojer N, Königsberg R, Ackermann J, et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood. 2000;95: 1925-1930.
9. Königsberg R, Zojer N, Ackermann J, et al. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. J Clin Oncol. 2000;18:804-812.
10. Tricot G, Barlogie B, Jagannath S, et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood. 1995;86: 4250-4256.
11. Tricot G, Sawyer JR, Jagannath S, et al. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol. 1997;15:2659-2666.
12. Seong C, Delasalle K, Hayes K, et al. Prognostic value of cytogenetics in multiple myeloma. Br J Haematol. 1998;101:189-194.
13. Desikan R, Barlogie B, Sawyer J, et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood. 2000;95:4008-4010.
14. Weh HJ, Gutensohn K, Selbach J, et al. Karyotype in multiple myeloma and plasma cell leukemia. Eur J Cancer. 1993;29A:1269-1273.
15. Dao DD, Sawyer JR, Epstein J, Hoover RG, Barlogie B, Tricot G. Deletion of the retinoblastoma gene in multiple myeloma. Leukemia. 1994;8: 1280-1284.
16. Laï JL, Zandecki M, Mary JY, et al. Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. Blood. 1995;85:2490-2497.
17. Calasanz MJ, Cigudosa JC, Odero MD, et al. Hypodiploidy and 22q11 rearrangements at diagnosis are associated with poor prognosis in patients with multiple myeloma. Br J Haematol. 1997;98: 418-425.
18. Smadia NV, Fruchart C, Isnard F, et al. Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases. Leukemia, 1998;12:960-969.
19. Durie BG, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842-854.
20. Kyle RA, Greipp PR. Smoldering multiple myeloma. N Engl J Med. 1980;302:1347-1349.
21. Kyle RA, Lust JA. Monoclonal gammopathies of undetermined significance. Semin Hematol. 1989;26:176-200.
22. Smadia NV, Louvet C, Isnard F, et al. Cytogenetic study in multiple myeloma at diagnosis: comparison of two techniques. Br J Haematol. 1995;90: 619-624.
23. Brigaudeau C, Trimoreau F, Gachard N, et al. Cytogenetic study of 30 patients with multiple myeloma: comparison of 3 and 6 day bone marrow cultures stimulated or not with cytokines by using a miniaturized karyotypic method. Br J Haematol. 1997;96:594-600.
24. Smadja NV, GFCH (Groupe Français de Cytogénétique Hématologique). Conventional cytogenetic in multiple myeloma: detection of karyotype abnormalities depends on technical and clinical factors [abstract]. Br J Haematol. 1998;102: P-1385.
25. Mitelman F, ed. An International System For Human Cytogenetic Nomenclature. Basel, Switzerland: S Karger; 1995.
26. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol. 1998;102:1115-1123.
27. Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc. 1958; 53:457-481.
28. Cox DR. Regression models and life tables. J R Stat Soc B. 1972;187-220.
29. Dewald GW, Kyle RA, Hicks GA, Greipp PR. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood. 1985;66: 380-390.
30. Gould J, Alexanian R, Goodacre A, Pathak S, Hecht B, Barlogie B. Plasma cell karyotype in multiple myeloma. Blood. 1988;71:453-456.
31. Taniwaki M, Nishida K, Takashima T, et al. Non-random chromosomal rearrangements of 14q32.3 and 19p13.3 and preferential deletion of 1 p in 21 patients with multiple myeloma and plasma cell leukemia. Blood. 1994;84:2283-2290.
32. Sawyer JR, Waldron JA, Jagannath S, Barlogie B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet. 1995; 82:41-49.
33. Calasanz MJ, Cigudosa JC, Odero MD, et al. Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: primary breakpoints and clinical correlations. Genes Chromosomes Cancer. 1997;18:84-93.
34. Laï JL, Michaux L, Dastugue N, et al. Cytogenetics in multiple myeloma: a multicenter study of 24 patients with t(11;14)(q13;q32) or its variant. Cancer Genet Cytogenet. 1998;104:133-138.
35. Fonseca R, Witzig TE, Gertz MA, et al. Multiple myeloma and the translocation t(11;14)(q13;q32): a report on 13 cases. Br J Haematol. 1998;101: 296-301.
36. Lerebourg F, Olschwang S, Thuille B, et al. Deletion mapping of the tumor suppressor locus involved in colorectal cancer on chromosome band 8p21. Genes Chromosomes Cancer. 1999;25: 147-153.
37. Shimazaki C, Inaba T, Shimura K, et al. B-cell lymphoma associated with haemophagocytic syndrome: a clinical, immunological and cytogenetic study. Br J Haematol. 1999;104:672-679.
38. Zandecki M, Bernardi F, Laï JL, et al. Image analysis in multiple myeloma at diagnosis: correlation with cytogenetic study. Cancer Genet Cytogenet. 1994;74:115-119.
39. Zandecki M, Laï JL, Facon T. Multiple myeloma: almost all patients are cytogenetically abnormal. Br J Haematol. 1996;94:217-227.
40. Drach J, Schuster J, Nowotny H, et al. Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization. Cancer Res. 1995;55:3854-3859.
41. Joshua D, Petersen A, Brown R, Pope B, Snowdon L, Gibson J. The labelling index of primitive plasma cells determines the clinical behaviour of patients with myelomatosis. Br J Haematol. 1996; 94:76-81.
42. Rajkumar SV, Fonseca R, Dewald GW, et al. Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma. Cancer Genet Cytogenet. 1999;113:73-77.
43. Rajkumar SV, Fonseca R, Lacy MQ, et al. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma. Bone Marrow Transplant. 1999;24:497-503.
44. Lee W, Han K, Drut RM, Harris CP, Meisner LF. Use of fluorescence in situ hybridization for retrospective detection of aneuploidy in Multiple Myeloma. Genes Chromosomes Cancer. 1993;7: 137-143.
45. Dubinsky R, Amiel A, Manor Y, et al. Fluorescence in situ hybridization (FISH) for retrospective detection of trisomies 3 and 7 in multiple myeloma. Cancer Genet Cytogenet. 1995;83:115-118.
46. Flactif M, Zandecki M, Laï JL, et al. Interphase fluorescence in situ hybridization (FISH) as a powerful tool for the detection of aneuploidy in multiple myeloma. Leukemia. 1995;9:2109-2114.
47. Tabernero D, San Miguel JF, Garcia-Sanz R, et al. Incidence of chromosome numerical changes in multiple myeloma: fluorescence in situ hybridization analysis using 15 chromosome-specific probes. Am J Pathol. 1996;149: 153-161.
48. Kearney L. The impact of the new FISH technologies on the cytogenetics of haematological malignancies. Br J Haematol. 1999;104:648-658.
49. Smith L, Badogie B, Alexanian R. Biclonal and hypodiploid multiple myeloma. Am J Med. 1986; 80:841-843.
50. Latreille J, Barlogie B, Dosik G, Johnston DA, Drewinko B, Alexanian R. Cellular DNA content as a marker of human multiple myeloma. Blood. 1980;55:403-408.
51. Barlogie B,Alexanian R, Dixon D, Smith L, Smallwood L, Delassalle K. Prognostic implications of tumor cell DNA and RNA content in multiple myeloma. Blood. 1985;66:338-341.
52. Morgan RJ, Gonchoroff NJ, Katzmann JA, Witzig TE, Kyle RA, Greipp PR. Detection of hypodiploidy using multi-parameter flow cytometric analysis: a prognostic indicator in multiple myeloma. Am J Hematol. 1989;30:195-200.
53. Garcia-Sanz R, Orfao A, Gonzalez M, et al. Prognostic implications of DNA aneuploidy in 156 untreated multiple myeloma patients. Br J Haematol. 1995;90:106-112.